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BACKGROUND: Phytoestrogens are of special interest in prostate cancer research because populations in Asia with a high consumption
of phytoestrogens have a lower incidence of the disease than comparable populations in Western countries.
METHODS: This case–control study is nested within a large multiethnic cohort in Hawaii and California. Urine samples were analysed
for daidzein, genistein, equol, and enterolactone among 249 incident prostate cancer cases and 404 controls matched on age, race/
ethnicity, date/time of specimen collection, and fasting status.
RESULTS: The median excretion of daidzein was 0.173nmolmg
 1 creatinine in cases and 0.291 in controls (P¼0.01), and the median
excretion of genistein was 0.048 in cases and 0.078 in controls (P¼0.05). An inverse association was seen for daidzein overall (odds
ratio for the highest vs lowest quintile¼0.55, 95% confidence interval¼0.31–0.98, Ptrend¼0.03) and seemed to apply to localized
(Ptrend¼0.08) as well as advanced or high-grade cancer (Ptrend¼0.09). This association was consistent across the four ethnic groups
examined. Although the relationship was weaker for genistein, the odds ratios and trends were similarly inverse. Urinary excretion of
equol and enterolactone was not significantly related to prostate cancer risk.
CONCLUSION: Our findings suggest that high intake of isoflavones, as reflected by urinary excretion of daidzein and genistein, may be
protective against prostate cancer.
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The incidence of prostate cancer is low in Asia, particularly China
and Japan, compared with Western countries including the United
States, Canada, and parts of Europe (Parkin et al, 2002). Diet has
been suggested as the cause of this international difference, and
phytoestrogens are of special interest, as their consumption as in
foods such as soy is much higher in Asia than in Western countries
(Adlercreutz, 2002; Messina, 2003). Phytoestrogens can be divided
into two main classes: isoflavones primarily found in soy and
lignans found in a wide range of plants (Magee and Rowland,
2004). Daidzein and genistein are major soy isoflavones and equol
is produced from daidzein by intestinal bacteria. The mammalian
lignans, enterodiol and enterolactone, are converted from plant
precursors by the gut bacteria in the colon (Kurzer and Xu, 1997;
Adlercreutz, 2002). Phytoestrogens may play a role in prostate
cancer through a variety of mechanisms, not all related to
estrogenic or antiestrogenic effects. Phytoestrogens act as free
radical scavengers and have effects on prostate-specific antigen
(PSA) production, androgen activity, apoptosis, angiogenesis,
sex hormone binding globulin, and gene expression (Magee and
Rowland, 2004). Although experimental studies have supported
such mechanisms and some epidemiologic studies found a
protective effect of dietary phytoestrogens against prostate cancer,
including a recent meta-analysis (Yan and Spitznagel, 2005), the
evidence from observational studies is not consistent (Ganry,
2005).
Urinary excretion of phytoestrogens has been shown to be a
valid biomarker of phytoestrogen intake (Maskarinec et al, 1998;
Seow et al, 1998; Chen et al, 1999; Lampe, 2003). Few studies,
however, have examined urinary phytoestrogens in relation to
prostate cancer risk (Low et al, 2006; Ward et al, 2008). In this
case–control study nested within a multiethnic cohort, we
assessed the effects of urinary excretion of daidzein, genistein,
equol, and enterolactone on prostate cancer risk.
MATERIALS AND METHODS
Study population and data collection
We carried out a nested case–control study within the Multiethnic
Cohort Study, established in Hawaii and Los Angeles, California, in
1993–1996 (Kolonel et al, 2000b). The study was approved by the
review boards of the University of Hawaii and the University of
Southern California. More than 215000 adults aged 45–75 years
entered the cohort by completing a detailed questionnaire on diet
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yand lifestyle factors, which targeted five ethnic/racial groups:
African Americans, Native Hawaiians, Japanese Americans,
Latinos, and Whites. A prospective biospecimen subcohort was
developed, largely between 2001 and 2006, when cohort members
who gave informed consent to participate provided a blood
and/or urine sample. An overnight (Hawaii) or a first morning
(Los Angeles) urine sample was preferentially collected; a spot
urine was requested otherwise.
Case ascertainment and control selection
Identification of incident, invasive prostate cancer cases was
accomplished through linkage to the population-based cancer
registries covering Hawaii and California, which are members of
the Surveillance, Epidemiology and End Results Program of the
National Cancer Institute. Deaths were identified by linkage to death-
certificate files in Hawaii and California, as well as to the National
Death Index. Advanced prostate cancers were defined as invasive
cancers that were regional or metastatic (not localized), whereas
high-grade prostate cancers were based on Gleason score (X7
categorized as poorly differentiated). During the follow-up period
(mean follow-up, 1.9 years), 467 eligible prostate cancer cases were
identified. Two controls for each cases were randomly selected from
the men who were alive and free of prostate cancer at the age of the
case’s diagnosis, by matching for geographic location (Hawaii or
California), race/ethnicity, birth year (±1y e a r ) ,d a t e( ±6m o n t h s )
and time (±2h) of specimen collection, and fasting hours (0–o6,
6–o8, 8–o10, and 10þ h). Out of these triplets, 288 cases and 540
controls had an overnight or first morning urine sample as required
for phytoestrogen assessment. This included 249 matched sets, 94
with one control and 155 with two controls (249 cases and 404
controls). The matching on area ensured that cases and controls with
a matched set used the same urine collection regime (i.e., overnight
in Hawaii or first morning in California).
Laboratory assays
Daidzein, genistein, equol, and enterolactone were analysed by
HPLC with electrospray ionization tandem mass spectrometry
using isotopically labelled internal standards of all four analytes
(Universities of St. Andrews, UK, and Helsinki, Finland), similar to
our earlier reports (Franke et al, 2002; Blair et al, 2003; Maskarinec
et al, 2008). Limits of quantitation (LOQ) were 1nM for daidzein
(all subjects4LOQ) and genistein (31oLOQ), 2nM for equol
(238oLOQ), and 5nM for enterolactone (4oLOQ). Between-day
coefficients of variation were 4–10% for daidzein, 5–12% for
genistein, 5–18% for equol, and 5–15% for enterolactone, whereas
intra-day variation was less than or equal to half of these values.
Statistical analyses
The differences in means and proportions between cases and
controls for several characteristics were tested, respectively, by the
t-test and w
2 test. As the distributions of urinary phytoestrogens
were skewed to the right, medians were tested by the Wilcoxon test
for differences between cases and controls. The sum of daidzein
and genistein was calculated as an estimate of main nonmetabo-
lized isoflavones and the sum of daidzein, genistein, and equol as
an estimate of major total isoflavonoids. Subjects were divided into
quantiles based on the overall distribution of urinary phytoestro-
gens in both cases and controls. For equol, the subjects with values
below the LOQ (n¼238, 36%) were assigned to the lowest quantile,
and the others were evenly divided into two groups. Conditional
logistic regression models were used to estimate odds ratios (ORs)
and 95% confidence intervals (CIs) of prostate cancer for the upper
quantile groups compared with the lowest quantile as a reference
group. To test for linear trend, a variable assigned the median of
the appropriate quantile was entered into the model as
a continuous variable. The significance of the trend was based
on the Wald statistic for the trend variable. Matched sets were used
as strata in the conditional logistic models, which accounted for
the matching criteria. The ORs were further adjusted for age at
specimen collection and fasting hours before specimen collection
as continuous variables to account for any possible systematic
differences within matched sets, as well as family history of
prostate cancer (yes vs no), body mass index (BMI, weight/
(height)
2; overweight and obese vs normal), and education
(continuous).
The models were run separately for localized but not high-grade
cases and their matched controls, and for advanced and/or high-
grade cases and their matched controls. The test of heterogeneity
across cancer stage/grade was performed by fitting the simultaneous
conditional logistic regressions for localized and advanced cancers
and testing an interaction between event type and exposure variable
by a likelihood ratio test. In an ethnic-specific analysis, Native
Hawaiians were not included because the number of cases was too
small (n¼6). Tests for interaction between urinary phytoestrogen
excretion and ethnicity in relation to prostate cancer risk were based
on likelihood ratios between models with and without interaction
terms. Separate analyses were performed excluding controls with
high PSA values (44ngml
 1) ,s t r a t i f y i n gb yB M Ic a t e g o r ya n d
smoking status, and restricting to equol producers, defined by an
equol to daidzein ratio of greater than 0.018 (Setchell and Cole, 2006).
These analyses used unconditional logistic regression to maximize
the number of subjects available and adjusted for the matching
criteria variables. Statistical significance was considered at Po0.05
and all tests were two sided.
RESULTS
There was no substantial difference in education, BMI, physical
activity, and family history of prostate cancer between cases and
controls (Table 1). The average time from specimen collection to the
case’s diagnosis date was 1.6 years in our analysis set and was not
different between cases and controls; this is less than the overall 1.9
years given earlier, as spot urines were collected from the earliest
participants in the repository, whereas the first morning/overnight
collection regimes were established later. The median excretion of
daidzein and genistein was lower in cases than in controls (P¼0.01
and 0.05, respectively), whereas the median excretion of equol and
enterolactone did not differ between the two groups.
The associations between urinary excretion of phytoestrogens
and prostate cancer risk are presented in Table 2. Urinary
excretion of daidzein was inversely associated with prostate cancer
risk: OR for the highest vs lowest quintile¼0.55, 95% CI¼0.31–
0.98, and Ptrend¼0.03. There was a nonsignificant inverse trend
for genistein (Ptrend¼0.09), for daidzeinþgenistein combined
(Ptrend¼0.07), and for equol (Ptrend¼0.08). When we limited the
analysis to equol producers (51%, 144 cases and 189 controls), no
significant association was found (Ptrend¼0.64). The results
remained similar when excluding controls with a high PSA value
(44ngml
 1, n¼62, data not shown).
Table 3 shows the relationship between phytoestrogens and
prostate cancer by stage/grade. For daidzein, an inverse linear
trend is suggested for both localized and advanced or high-grade
tumours, although the P values for trend (0.08 and 0.09,
respectively) are not quite statistically significant. For genistein,
the ORs for the highest tertiles were also below 1.00 for both
localized and advanced or high-grade disease, though the trends
were not statistically significant. Similar patterns were seen for the
combinations of daidzein, genistein, and equol. There was no
statistically significant heterogeneity in ORs across stage/grade,
except for enterolactone (Pinteraction¼0.02), which showed a
nonsignificant increased risk in the third tertile for advanced or
high-grade tumours.
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limited, so we could only dichotomize the urinary excretion at the
median. Table 4 shows the results for four ethnic groups (the number
of cases in Native Hawaiians was too few for a separate analysis).
None of the interactions were significant. The association of daidzein
with prostate cancer risk was inverse for all four ethnic groups,
although only Latinos showed a statistically significant reduction. For
genistein, an inverse association was seen for two of the four groups.
Table 1 Characteristics of cases and controls
a
Cases (n¼249) Controls (n¼404) P-value
b
Age at specimen collection (years) 69.2±6.7
c 69.2±6.9 0.96
Time between specimen collection and case diagnosis (years) 1.6±1.5 1.5±1.4 0.49
Fasting hours before specimen collection 12.7±3.3 13.0±3.2 0.32
Education (years) 14.0±2.8 14.0±2.9 0.71
Body mass index (kgm
 2) 25.8±3.9 26.0±3.7 0.45
METS of activity per day 1.64±0.28 1.64±0.30 0.93
Family history of prostate cancer (%) 10.0 7.7 0.29
Ethnicity (%)
African Americans 37.0
d 32.9 0.80
Native Hawaiians 2.4 2.7
Japanese Americans 28.1 30.2
Latinos 17.7 16.8
Whites 14.9 17.3
Urinary phytoestrogens
e
Daidzein 0.173 (0.057, 0.652)
f 0.291 (0.084, 1.307) 0.01
Genistein 0.048 (0.013, 0.303) 0.078 (0.016, 0.495) 0.05
Equol 0.005 (oLOQ
g, 0.017) 0.004 (oLOQ, 0.013) 0.42
Daidzein+Genistein 0.235 (0.081, 1.015) 0.428 (0.112, 1.996) 0.01
Daidzein+Genistein+Equol 0.257 (0.094, 1.194) 0.438 (0.118, 2.112) 0.03
Enterolactone 1.042 (0.273, 2.327) 1.094 (0.401, 2.253) 0.97
aMatching for geographic location (Hawaii or California), race/ethnicity, birth year (±1 year), date (±6 months) and time (±2h) of specimen collection, and fasting hours
(0–o6, 6–o8, 8–o10, and 10+h).
bTested by t-test (means), w
2 test (percentages), and Wilcoxon rank-sum test (medians).
cMean±s.d.
dColumn percentage.
eExpressed as
nmolmg
 1 creatinine.
fMedian (25th, 75th percentile).
goLOQ, less than limit of quantitation.
Table 2 Associations of urinary phytoestrogen excretion with prostate cancer risk
a
Q1 Q2 Q3 Q4 Q5 P-value for linear trend
Daidzein p0.053
b 0.053–p0.151 0.151–p0.386 0.386–p1.630 41.630
Cases/controls 59/71 57/75 48/81 45/86 40/91
OR (95% CI) 1.00 1.03 (0.61–1.74) 0.83 (0.50–1.38) 0.74 (0.44–1.25) 0.55 (0.31–0.98) 0.03
Genistein p0.009 0.009–p0.038 0.038–p0.126 0.126–p0.729 40.729
Cases/controls 54/76 62/70 46/87 45/85 42/89
OR (95% CI) 1.00 1.48 (0.88–2.49) 0.91 (0.53–1.55) 0.99 (0.59–1.69) 0.72 (0.40–1.31) 0.09
Equol p0.001 0.001–p0.010 40.010
Cases/controls 90/148
c 70/137 89/119
OR (95% CI) 1.00 0.89 (0.58–1.37) 1.32 (0.84–2.08) 0.08
Equol (producers only)
d p0.005 0.005–p0.023 40.023
Cases/controls 47/64 47/64 50/61
OR (95% CI) 1.00 1.05 (0.59–1.85) 1.32 (0.72–2.42) 0.64
Daidzein+Genistein p0.069 0.069–p0.202 0.202–p0.522 0.522–p2.565 42.565
Cases/controls 56/74 62/69 44/86 45/87 42/88
OR (95% CI) 1.00 1.38 (0.83–2.30) 0.74 (0.44–1.24) 0.83 (0.49–1.39) 0.63 (0.35–1.14) 0.07
Daidzein+Genistein+Equol p0.077 0.077–p0.213 0.213–p0.549 0.549–p2.773 42.773
Cases/controls 56/74 58/73 47/84 44/86 44/87
OR (95% CI) 1.00 1.27 (0.76–2.21) 0.84 (0.51–1.40) 0.86 (0.51–1.44) 0.74 (0.42–1.30) 0.19
Enterolactone p0.227 0.227–p0.798 0.798–p1.493 1.493–p2.667 42.667
Cases/controls 57/74 47/83 38/92 55/77 52/78
OR (95% CI) 1.00 0.71 (0.42–1.21) 0.58 (0.34–0.98) 0.97 (0.57–1.66) 0.98 (0.58–1.66) 0.44
aMatching for geographic location (Hawaii or California), race/ethnicity, birth year (±1 year), date (±6 months) and time (±2h) of specimen collection, and fasting hours
(0–o6, 6–o8, 8–o10, and 10+h). The models were adjusted for age at specimen collection and fasting hours as continuous variables, as well as family history of prostate
cancer, BMI, and education.
bExpressed as nmolmg
 1 creatinine.
cSubjects with values below the limit of quantitation.
dUnconditional logistic regression was used with adjustment
for the matching criteria and the same covariates as in conditional logistic models.
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was no statistically significant association or interaction (data not
shown). However, the number of cases in each cell, particularly for
the obese group and the current smokers, were too small for stable
estimates.
DISCUSSION
In this case–control study nested within a multiethnic cohort, we
found an inverse association between urinary daidzein excretion
and prostate cancer risk. A suggestive inverse trend for daidzein
was seen for localized, as well as advanced or high-grade cancer,
and across the four ethnic groups examined. Urinary excretion of
genistein, equol, and enterolactone was not significantly related to
prostate cancer risk.
In earlier observational studies, dietary intake of isoflavones or
soy product consumption was inversely associated with prostate
cancer risk in some (Severson et al, 1989; Jacobsen et al, 1998;
Strom et al, 1999; Kolonel et al, 2000a; Lee et al, 2003; Sonoda et al,
2004; Hedelin et al, 2006a; Heald et al, 2007; Kurahashi et al, 2007;
Nagata et al, 2007), but not all reports (Sung et al, 1999; Villeneuve
Table 3 Associations of urinary phytoestrogen excretion with prostate cancer risk by tumour characteristics
a
T1 T2 T3 P-value for linear trend P-value for heterogeneity
b
Daidzein p0.115
c 0.115–p0.569 40.569
Localized
d 0.83
Cases/controls 53/70 46/66 36/84
OR (95% CI) 1.00 0.93 (0.55–1.59) 0.59 (0.31–1.11) 0.08
Advanced or high grade
Cases/controls 26/33 24/37 18/33
OR (95% CI) 1.00 0.98 (0.41–2.36) 0.46 (0.17–1.27) 0.09
Genistein p0.024 0.024–p0.200 40.200
Localized 1.00
Cases/controls 52/68 44/69 39/83
OR (95% CI) 1.00 1.01 (0.59–1.73) 0.74 (0.38–1.42) 0.32
Advanced or high grade
Cases/controls 31/34 18/40 47/28
OR (95% CI) 1.00 0.53 (0.23–1.20) 0.53 (0.21–1.37) 0.37
Equol p0.001 0.001–p0.010 40.010
Localized 0.66
Cases/controls 50/85
e 34/63 51/72
OR (95% CI) 1.00 1.10 (0.60–2.03) 1.38 (0.75–2.54) 0.29
Advanced or high grade
Cases/controls 22/27
e 21/48 25/27
OR (95% CI) 1.00 0.54 (0.22–1.31) 1.17 (0.42–3.23) 0.19
Daidzein+Genistein p0.150 0.150–p0.799 40.799
Localized 0.88
Cases/controls 54/69 44/66 37/85
OR (95% CI) 1.00 0.85 (0.49–1.48) 0.57 (0.30–1.09) 0.10
Advanced or high grade
Cases/controls 28/34 23/37 17/31
OR (95% CI) 1.00 1.04 (0.45–2.38) 0.44 (0.16–1.18) 0.07
Daidzein+Genistein+Equol p0.159 0.159–p0.847 40.847
Localized 0.96
Cases/controls 54/67 43/69 38/84
OR (95% CI) 1.00 0.84 (0.49–1.45) 0.61 (0.32–1.16) 0.16
Advanced or high grade
Cases/controls 28/37 22/35 18/30
OR (95% CI) 1.00 0.99 (0.44–2.23) 0.51 (0.19–1.34) 0.14
Enterolactone p0.616 0.616–p1.771 41.771
Localized 0.02
Cases/controls 51/71 43/85 41/64
OR (95% CI) 1.00 0.79 (0.46–1.36) 0.87 (0.47–1.60) 0.74
Advanced or high grade
Cases/controls 21/31 16/36 31/35
OR (95% CI) 1.00 0.76 (0.31–1.87) 1.60 (0.74–3.50) 0.12
aMatching for geographic location (Hawaii or California), race/ethnicity, birth year (±1 year), date (±6 months) and time (±2h) of specimen collection, and fasting hours (0–
o6, 6–o8, 8–o10, and 10+h). The models were adjusted for age at specimen collection and fasting hours as continuous variables, as well as family history of prostate cancer,
BMI, and education. Forty-six cases were missing stage/grade.
bThe P for heterogeneity between localized and advanced or high grade cancers is based on the likelihood ratio test.
cExpressed as nmolmg
 1 creatinine.
dLocalized but not of high grade.
eSubjects with values below the limit of quantitation.
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yet al, 1999; Allen et al, 2004; Nomura et al, 2004; Low et al, 2006;
Hedelin et al, 2006b). A meta-analysis of soy food consumption
and prostate cancer, including two cohort and six case–control
studies, reported a 30% overall risk reduction (Yan and Spitznagel,
2005). There are only a few studies that have examined biomarkers
of isoflavone intake in relation to prostate cancer risk. In a nested
case–control study of Japanese men, Ozasa et al (2004) found that
high serum levels of genistein, daidzein, and equol were associated
with a decreased risk of prostate cancer. Two reports from
the European Prospective Investigation of Cancer-Norfolk Study
(Low et al, 2006; Ward et al, 2008) did not find any association
of either serum or urinary isoflavones with prostate cancer risk.
Also, a case–control study in Scottish men reported no association
between serum isoflavones and prostate cancer risk (Heald et al,
2007).
The extent of urinary isoflavone excretion would be expected to
be higher and the ranges wider in our study population than in the
populations of most Western countries, because 29% of the
subjects in our study were Japanese Americans who consume
relatively high amounts of soy products. In our controls, the
median values (0.29nmolmg
 1 creatinine for daidzein and 0.08 for
genistein) were similar to those reported for the US adult (X20
years) population (0.23 for daidzein and 0.08 for genistein)
(Valentin-Blasini et al, 2005), whereas they were much less than
in the Singapore population where the medians were 1.37 for
daidzein and 0.73 for genistein (Seow et al, 1998). However, there
were substantial differences across the racial/ethnic groups,
ranging from 0.13nmolmg
 1 creatinine in African Americans to
1.12 in Japanese Americans for daidzein, and from 0.03 in African
Americans to 0.74 in Japanese Americans for genistein confirming
our earlier findings in women (Maskarinec et al, 1998).
In this study, the reason that the effect of genistein on prostate
cancer risk was not as strong as that of daidzein is not clear,
although the correlation between these two isoflavones in urine
was high (r¼0.90, Po0.001). In serum or plasma, genistein
concentrations are generally higher than daidzein, whereas the
opposite occurs in urine (Lampe, 2003). This suggests that the
metabolism and excretion of these isoflavones are not identical
and explains the higher bioavailability of genistein compared with
daidzein (Franke et al, 2009). As urinary excretion of daidzein and
genistein reflect the corresponding circulating levels equally well,
that is, plasma/urine ratios of both daidzein and genistein are
constant within and between individuals (Franke et al, 2004),
daidzein may have a greater potential to prevent prostate cancer
than does genistein. The enhanced rate of glucuronidation of
estrogen by daidzein and its metabolites may explain the
protective effect of soy isoflavones against hormonal cancers
(Pfeiffer et al, 2005). Daidzein may also be a surrogate for the
effects of its metabolite equol that was shown to specifically bind
5alpha-dihydrotestosterone (DHT) and thereby inhibit DHT’s
stimulation of prostate cell growth (Lund et al, 2004), although
we did not observe any association between equol and prostate
cancer risk in this study.
Previously, in a prospective analysis of the entire multiethnic
cohort (n¼82483 including 4404 cases), we found a modest risk
reduction for total prostate cancer in men with highest soy intake
(relative risk (RR)¼0.90, 95% CI¼0.80–1.01) and a stronger
effect for advanced or high-grade prostate cancer (RR¼0.78, 95%
CI¼0.62–0.98) (Park et al, 2008). However, we found no
significant association with estimated intakes of genistein or
daidzein. Although we used our valid quantitative food frequency
questionnaire and comprehensive food composition table, there
might be more measurement error in these estimates than in the
biomarker assays. Furthermore, the food composition table might
not capture all sources of phytoestrogens in the diet. However,
urinary excretion of isoflavones has been shown to have a linear
Table 4 Associations of urinary phytoestrogen excretion with prostate cancer risk by race/ethnicity
a
African Americans Japanese Americans Latinos Whites
Cases/
controls OR (95% CI)
Cases/
controls OR (95% CI)
Cases/
controls OR (95% CI)
Cases/
controls OR (95% CI)
P for
interaction
b
Daidzein
p0.234
c 68/87 1.00 19/27 1.00 31/33 1.00 22/30 1.00
40.234 24/46 0.75 (0.39–1.45) 51/95 0.71 (0.35–1.42) 13/35 0.38 (0.16–0.92) 15/40 0.47 (0.19–1.20) 0.65
Genistein
p0.067 64/91 1.00 16/26 1.00 30/37 1.00 23/31 1.00
40.067 28/42 1.28 (0.69–2.38) 54/96 0.92 (0.44–1.95) 14/31 0.52 (0.23–1.21) 14/39 0.42 (0.17–1.06) 0.34
Equol
p0.004 53/77 1.00 33/66 1.00 17/35 1.00 12/26 1.00
40.004 39/56 1.06 (0.53–2.11) 37/56 1.62 (0.80–3.28) 27/33 2.14 (0.76–6.03) 25/44 1.27 (0.48–3.37) 0.85
Daidzein+Genistein
p0.326 68/90 1.00 18/24 1.00 31/32 1.00 23/31 1.00
40.326 24/43 0.84 (0.43–1.64) 52/98 0.63 (0.31–1.29) 13/36 0.37 (0.16–0.87) 14/39 0.41 (0.16–1.10) 0.54
Daidzein+Genistein
+Equol
p0.335 68/91 1.00 18/23 1.00 31/32 1.00 21/32 1.00
40.335 24/42 0.90 (0.46–1.76) 52/99 0.61 (0.30–1.26) 13/36 0.32 (0.13–0.80) 16/38 0.56 (0.21–1.46) 0.55
Enterolactone
p1.091 44/63 1.00 47/72 1.00 19/35 1.00 12/23 1.00
41.091 48/70 1.02 (0.54–1.94) 23/50 0.67 (0.34–1.31) 25/33 1.76 (0.74–4.19) 25/47 1.17 (0.47–2.92) 0.33
aMatching for geographic location (Hawaii or California), race/ethnicity, birth year (±1 year), date (±6 months) and time (±2h) of specimen collection, and fasting hours
(0–o6, 6–o8, 8–o10, and 10+h). The models were adjusted for age at specimen collection and fasting hours as continuous variables, as well as family history of prostate
cancer, BMI, and education.
bThe P for interaction between urinary phytoestrogen excretion and ethnicity is based on the likelihood ratio test.
cExpressed as nmolmg
 1
creatinine.
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and observational studies (Lampe, 2003). In earlier studies, urinary
isoflavone excretion was significantly correlated with usual
isoflavone intake in women from a multiethnic population in
Hawaii (r¼0.31, Po0.01) (Maskarinec et al, 1998), and with usual
soy food consumption among women in Shanghai (r¼0.50,
Po0.001) (Chen et al, 1999).
Equol is a product of intestinal bacterial metabolism of daidzein,
and it has estrogenic activity (Setchell et al, 2002). In the studies in
European countries, urinary and/or serum equol were not related
to prostate cancer (Low et al, 2006; Heald et al, 2007; Ward et al,
2008), whereas the study among Japanese men where soy intake
was much higher found an inverse association between serum
equol and prostate cancer risk (Ozasa et al, 2004). Whether we
restricted the analyses to equol producers or not, we observed no
relation of urinary equol excretion with prostate cancer risk.
One case–control study found a 60% reduction in prostate cancer
risk associated with a high concentration of serum enterolactone
(Heald et al, 2007), but no relationship was seen in other studies that
measured enterolactone in serum, plasma, or urine (Stattin et al,
2002, 2004; Kilkkinen et al, 2003; Low et al, 2006; Hedelin et al,
2006b). One possible reason for the lack of associations in earlier
studies is that enterolactone levels were too low for a protective effect
to be observed (Heald et al, 2007). In our study, urinary
enterolactone excretion (median¼1.09nmolmg
 1 creatinine in
controls) was lower than in the study of Low et al in the UK
(mean¼2.06nmolmg
 1 creatinine in controls) (Low et al, 2006) and
similar to that in the US adult population (median¼0.96nmolmg
 1
creatinine) (Valentin-Blasini et al, 2005). Thus, our failure to observe
an association with prostate cancer risk was possibly due to the low
excretion of enterolactone in our population.
Our prospective design reduced the possibility that the disease
influenced either dietary intake or urinary excretion of phyto-
estrogens. Furthermore, when we excluded controls with elevated
PSA levels (44ngml
 1) (some of whom may have had
undiagnosed prostate tumours), the results did not change. The
different ethnic groups led to a wide range in concentration of
measured analytes thereby minimizing the risk of not being able to
observe effects within or between the low and high phytoestrogen
exposed groups. Although this is a relatively small study, we were
able to detect as significant a linear trend in ORs from 1 to 0.55
across daidzein quintiles (P¼0.03). The minimum detectable OR
in quintile 5, assuming a linear trend in ORs, a power of 80% and a
critical value of 0.05, was 0.56. Therefore, our power to detect a
more modest OR of 0.72, as found for genistein, was suboptimal.
However, certain limitations must be considered in this study.
Urinary isoflavones reflect short term (24–48h) rather than long-
term dietary intake (Franke et al, 2004). Furthermore, only one
overnight or first morning urine sample was collected and, thus,
might not represent usual intake, although three measurements of
urinary isoflavone excretion over a 3-week period were in
acceptable agreement in a pilot study that was conducted among
20 individuals (unpublished). As dietary intake was not assessed at
the time of urine collection, we were not able to look at how well
urinary isoflavone excretion correlated with usual intake of
isoflavones among our subjects. However, a study using a one-
time urine sample reported that urinary isoflavones represented
usual intakes of dietary isoflavone as measured by 24h dietary
recall in US adults (Chun et al, 2009). Follow-up time (average 1.6
years) was relatively short, and thus further studies in this cohort
will be of interest when more follow-up has accrued. Another
limitation is reduced statistical power for the subgroup analyses
due to the smaller number of cases.
In conclusion, high urinary excretion of the soy isoflavones,
especially daidzein, seemed to be protective against prostate cancer
in a multiethnic population in which the variation of isoflavones in
urine was wide.
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